Patents Assigned to Office of Technology Transfer National Institute of Health
  • Indenoisoquinolines as antineoplastic agents
    Patent number: 6509344
    Abstract: A number of indenoisoquinolines were prepared and evaluated for cytotoxicity in human cancer cell cultures and for activity versus topoisomerase I. The two most cytotoxic indenoisoquinolines proved to be cis-6-ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8,9(methylenedioxy)-5,11-dioxo-11H-indeno[1,2-c]isoquinoline and cis-6-allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8,9-(methylenedioxy)-5,11-dioxo-(11H)indeno[1,2-c]isoquinoline. Two of the most potent topoisomerase I inhibitors were 6-(3-carboxy-1-propyl)-5,6-dihydro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (26) and 6-ethyl-2,3-dimethoxy-8,9-(methylenedioxy)-11H-indeno[1,2-c]isoquinolinium chloride (27).
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: January 21, 2003
    Assignees: The United States of America as represented by the Department of Health and Human Services, Office of Technology Transfer National Institute of Health
    Inventors: Mark S. Cushman, Pamela M. Nagafuji, Muthusamy Jayaraman, Yves G. Pommier
  • Nitric oxide-releasing medical devices
    Publication number: 20020119115
    Abstract: A polymeric composition capable of releasing nitric oxide under physiological conditions which includes a biopolymer, such as a peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing N2O2− functional group; pharmaceutical compositions comprising the polymeric composition; and methods of treating biological disorders in which dosage with nitric oxide is therapeutic.
    Type: Application
    Filed: January 8, 2002
    Publication date: August 29, 2002
    Applicant: Office of Technology Transfer, National Institutes of Health
    Inventors: Larry K. Keefer, Joseph A. Hrabie